» Articles » PMID: 38030655

Non-canonical Pathway for Rb Inactivation and External Signaling Coordinate Cell-cycle Entry Without CDK4/6 Activity

Overview
Journal Nat Commun
Specialty Biology
Date 2023 Nov 29
PMID 38030655
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin-dependent kinases 4 and 6 (CDK4/6) are critical for initiating cell proliferation by inactivating the retinoblastoma (Rb) protein. However, mammalian cells can bypass CDK4/6 for Rb inactivation. Here we show a non-canonical pathway for Rb inactivation and its interplay with external signals. We find that the non-phosphorylated Rb protein in quiescent cells is intrinsically unstable, offering an alternative mechanism for initiating E2F activity. Nevertheless, this pathway incompletely induces Rb-protein loss, resulting in minimal E2F activity. To trigger cell proliferation, upregulation of mitogenic signaling is required for stabilizing c-Myc, thereby augmenting E2F activity. Concurrently, stress signaling promotes Cip/Kip levels, competitively regulating cell proliferation with mitogenic signaling. In cancer, driver mutations elevate c-Myc levels, facilitating adaptation to CDK4/6 inhibitors. Differentiated cells, despite Rb-protein loss, maintain quiescence through the modulation of c-Myc and Cip/Kip levels. Our findings provide mechanistic insights into an alternative model of cell-cycle entry and the maintenance of quiescence.

Citing Articles

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies.

Lopez J, Llop-Hernandez A, Verdura S, Serrano-Hervas E, Martinez-Balibrea E, Bosch-Barrera J Cell Death Discov. 2025; 11(1):91.

PMID: 40055336 PMC: 11889205. DOI: 10.1038/s41420-025-02379-y.


Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.


Targeting CDK4/6 in breast cancer.

Shanabag A, Armand J, Son E, Yang H Exp Mol Med. 2025; 57(2):312-322.

PMID: 39930131 PMC: 11873051. DOI: 10.1038/s12276-025-01395-3.


The interplay of p16INK4a and non-coding RNAs: bridging cellular senescence, aging, and cancer.

Balaraman A, Afzal M, Moglad E, Babu M, Priya G, Bansal P Biogerontology. 2025; 26(2):50.

PMID: 39907830 DOI: 10.1007/s10522-025-10194-2.


Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.

Armand J, Kim S, Kim K, Son E, Kim M, Yang H bioRxiv. 2024; .

PMID: 39605351 PMC: 11601343. DOI: 10.1101/2024.11.11.623139.


References
1.
Iwamoto M, Bjorklund T, Lundberg C, Kirik D, Wandless T . A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol. 2010; 17(9):981-8. PMC: 2943492. DOI: 10.1016/j.chembiol.2010.07.009. View

2.
Sherr C . D-type cyclins. Trends Biochem Sci. 1995; 20(5):187-90. DOI: 10.1016/s0968-0004(00)89005-2. View

3.
Leonce C, Saintigny P, Ortiz-Cuaran S . Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer. Mol Cancer Res. 2021; 20(1):11-29. DOI: 10.1158/1541-7786.MCR-21-0038. View

4.
Marine J, Dawson S, Dawson M . Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020; 20(12):743-756. DOI: 10.1038/s41568-020-00302-4. View

5.
Pajalunga D, Crescenzi M . Restoring the Cell Cycle and Proliferation Competence in Terminally Differentiated Skeletal Muscle Myotubes. Cells. 2021; 10(10). PMC: 8534385. DOI: 10.3390/cells10102753. View